Compare Amkor Technology (AMKR) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amkor Technology vs Sanofi SA — how do they compare? Amkor Technology trades at $51.73 (market cap $12.85B), while Sanofi SA trades at $42.77 (market cap $101.90B). The key difference: Sanofi SA is far larger — about 7.9× Amkor Technology's market cap, and Sanofi SA pays the higher dividend (5.66%). Which is the better fit depends on your goals.
| AMKR | SNY | |
|---|---|---|
Market Cap | $12.85B | $101.90B |
Sector | Technology | Health |
52-Week High | $93.55 | $52.34 |
52-Week Low | $25.46 | $41.33 |
Enterprise Value | $12.93B | $121.89B |
Dividend Yield | 0.65% | 5.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMKR trades at $51.73, up 4.44% today, with a neutral technical signal. The company reported strong earnings beats in recent quarters and is expanding its Arizona advanced packaging campus with a $12 billion investment. Revenue grew to $6.71 billion in 2025, with net income of $373.90 million, and is projected to reach $7.5 billion in 2026. Analyst consensus is bullish with a $77.00 price target, representing significant upside potential.
The outlook is positive driven by AI and semiconductor demand, partnerships with TSMC and NVIDIA, and global expansion. Risks include execution of the large capital expenditure plan, competitive pressures, and market volatility. Institutional interest is strong, with recent investments from BlackRock and Canada Pension Plan, supporting long-term growth prospects.
Sanofi (SNY) trades at $42.77, up 0.12% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 2025 revenue of $46.72B and net income of $7.81B, supported by a 72.77% gross margin. Recent FDA approvals for COVID-19 and RSV vaccines provide growth catalysts, though pipeline setbacks and competitive pressures remain concerns.
Outlook remains mixed with analyst consensus leaning Hold (51.86%) amid valuation discounts. Key opportunities include Dupixent's growth trajectory and new product launches, while risks involve patent expirations and regulatory hurdles. The stock's current P/E of 22.69 suggests reasonable valuation relative to sector peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amkor Technology
Amkor Technology provides outsourced semiconductor packaging and test services. It helps chipmakers assemble, protect, and test semiconductors for computing, communications, automotive, and consumer applications.
Read more on AMKR →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
